Innovation with patient’s needs in mind

MAXONA was founded with the goal of addressing the needs of those searching for safe and efficacious remedies as alternatives to NSAIDs and opioid analgesics for the treatment of pain.

​​MAXONA will undertake a staged approach to developing MAX-001 as a platform for treatment of moderate to severe pain:

• Stage 1 – Acute pain.
• Stage 2 – Chronic pain & additional other dosage forms and indications some of which are considered as orphan disorders.

Thoughtful approach to drug development

MAXONA is poised to leverage MAX-001 and build a pipeline of novel therapeutics focused on various pain indications by capitalizing on the existing extensive worldwide safety and efficacy data available as a result of nearly four decades of use.

We have adopted a comprehensive patent strategy and built a suite of applied and issued patents covering multiple Compositions of Matter and Methods of Use for MAX-001 targeted at a variety of disorders of pain.